Announcement PDF ONCOSIL MEDICAL LIMITED ABN 89 113 824 141 ASX | OSL Level 5, 7 Eden Park Drive, Macquarie Park, NSW 2113 AUSTRALIA TELEPHONE +61 2 8935 9629 WEB www.oncosil.com 1 ASX Announcement 24 February 2026 Half Yearly Report – Appendix 4D Six Months Ended 31 December 2025 OncoSil Medical Reports Record Cash Receipts and Dose Sales in 1H FY26 Key Operational Highlights • Record cash receipts and dose sales reported in the six months ended 31 December 2025 (1H FY26) • Positive preliminary results from PANCOSIL Phase 1-2 Study announced at the CIRSE 2025 Congress • Board leadership transition and director appointments • First OncoSil™ treatments in Portugal, Germany and the UK • OSPREY registry analysis shows Survival Benefit for OncoSil™ patients in a real-world setting • Successful OncoSil™device production run at new Sydney Facility OncoSil Medical CEO & Managing Director Nigel Lange said: “The first half of FY26 has been a defining period for OncoSil, marked by record dose sales and cash receipts, expanding commercial adoption across key European markets, in addition to a growing body of encouraging clinical evidence supporting treatment with the OncoSil™ device. The positive preliminary data from the PANCOSIL study, encouraging real-world outcomes from the OSPREY registry, and completion of key clinical milestones such as TRIPP-FFX LPLV reinforce our confidence in the safety, feasibility, and potential efficacy of our technology. Alongside important advances in manufacturing capability, regulatory progress, and a strengthened balance sheet following our recent capital raise, these achievements position the Company strongly for the second half as we focus on broadening access, advancing regulatory label approvals, and delivering meaningful outcomes for patients with locally advanced pancreatic cancer.” Operational Developments Record dose sales and cash receipts reported in 1H FY26 OncoSil Medical achieved record dose sales in 1H FY26, with doses sold increasing by 100% compared to 1H FY25. Growth was driven by both direct to hospital and distributor sales, reflecting rising clinical adoption and expanded commercial activity across key markets. This momentum translated into revenue growth of 70.5% versus 1H FY25, across both sales channels. The Company also reported record cash receipts of $1.2 million in 1H FY26, representing an 184.0% increase compared to the prior corresponding period. ONCOSIL MEDICAL LIMITED ABN 89 113 824 141 ASX | OSL Level 5, 7 Eden Park Drive, Macquarie Park, NSW 2113 AUSTRALIA TELEPHONE +61 2 8935 9629 WEB www.oncosil.com 2 Positive Preliminary Results from PANCOSIL Phase 1-2 Study announced at CIRSE 2025 In September 2025, preliminary results from the PANCOSIL Investigator-Initiated Phase 1–2 Study were presented by Dr Danielle Vos of Amsterdam University Medical Centre at the CIRSE 2025 Congress in Barcelona. The data demonstrated that CT-guided percutaneous administration of OncoSil™ is both safe and feasible in patients with locally advanced pancreatic cancer (LAPC). Among 20 treated patients, no procedure-related deaths were reported. Two Grade 3 serious adverse events occurred—one procedure-related and one possibly device-related—with both patients making a full recovery. The procedure achieved a technical success rate of 90%, supporting its reliability and potential to reduce procedure time and patient recovery burden. Encouraging early efficacy signals were also observed in a group of patients who had undergone several cycles of treatment with FOLFIRINOX chemotherapy, including a 15% partial response rate and a median overall survival of 20.6 months, which compares favourably with the historical median overall survival of approximately 13 months for LAPC. Based on these findings, OncoSil intends to submit a change notification request with the Notified Body, British Standards Institute (BSI) in 2H FY26 for the CT-guided percutaneous administration approach. This advancement has the potential to broaden treatment accessibility by enabling delivery by interventional radiologists, a rapidly expanding specialty within oncology. The Company plans to seek label expansion across the European Union and other regions, while fostering closer collaboration between interventional radiologists, oncologists, and surgeons to support broader global adoption of OncoSil™ therapy. Board Leadership Transition and Director Appointments In July 2025, Dr Thomas Duthy was appointed as a Non-Executive Director of OncoSil Medical, bringing more than 22 years of experience across healthcare, corporate development, and financial markets, including his pivotal role in Sirtex Medical’s $1.9 billion acquisition, the largest medical device transaction in Australian history. Dr Duthy subsequently assumed the role of Non-Executive Chairman effective 1 October 2025 with Mr Douglas Cubbin stepping down as Chairman on the same day to assume a Non-Executive Director role. In November 2025, Mr Cubbin notified the Company of his intention to retire and not stand for re- election at the Annual General Meeting. Mr Cubbin joined the Company as a Non-Executive Director on 7 August 2023 and was appointed Chairman later that month. OncoSil Medical sincerely thanks Mr Cubbin for his leadership, commitment, and valuable contribution during his tenure, wishing him well in his future endeavours. These changes reinforce the Company’s strategic focus on advancing its position in the oncology device sector. First OncoSil™ treatments in Germany, the UK and Portugal In 1H FY26, OncoSil Medical achieved significant European commercial milestones with the successful first patient treatments using its OncoSil™ device in Germany, the United Kingdom, and Portugal. In Germany, the initial treatment was successfully completed at Universitätsklinikum Augsburg, marking the Company’s commercial entry into Europe’s largest healthcare market and reflecting growing clinical adoption and confidence in OncoSil™. In the United Kingdom, the first commercial treatment ONCOSIL MEDICAL LIMITED ABN 89 113 824 141 ASX | OSL Level 5, 7 Eden Park Drive, Macquarie Park, NSW 2113 AUSTRALIA TELEPHONE +61 2 8935 9629 WEB www.oncosil.com 3 at Southampton General Hospital signalled the transition of the technology from clinical evaluation to routine commercial use. In Portugal, the first commercial procedure was performed at the Instituto Português de Oncologia do Porto (IPO Porto), one of Europe’s leading cancer centres, expanding patient access to OncoSil™ for locally advanced pancreatic cancer. Collectively, these milestones underscore OncoSil Medical’s accelerating European rollout and its commitment to delivering innovative cancer therapies across major healthcare systems. OSPREY Registry Analysis Survival Benefit for OncoSil™ Patients in a Real-World Setting In December 2025, OncoSil Medical announced the submission of an abstract to the ESGE Days Congress, to be held in Milan, Italy from 14–16 May 2026, presenting key findings from the first interim analysis of the OncoSil™ Pancreatic Cancer Post-Marketing Clinical Registry (OSPREY). The analysis includes data from 64 patients with unresectable locally advanced pancreatic cancer (LAPC) treated with the OncoSil™ device alongside gemcitabine-based chemotherapy across 19 centres in Europe. Among first-line patients, who represented 75% of the registry population, median overall survival was 20.6 months from the time of diagnosis in patients implanted with OncoSil™ within four months of commencing chemotherapy, and 22.0 months from the time of diagnosis in those implanted between four and twelve months after starting chemotherapy. The registry demonstrated a favourable safety profile, with mild adverse device events reported in 15.6% of patients and no serious device-related events, acute complications, pancreatitis, or hospital admissions. Successful OncoSil™ Device Production Run at New Sydney Facility In December 2025, OncoSil Medical successfully completed its first hot (radioactive) production test run at the Sydney manufacturing facility, achieving a key risk-managed milestone. The test confirmed the facility’s ability to manufacture the approved OncoSil™ device under full production conditions using standard equipment, materials, and processes, supporting the ongoing regulatory review with facility approval expected in 2H CY26, subject to completion of required steps. This milestone aligns with the Company’s strategy to strengthen in-house manufacturing, improve supply chain resilience, and, following regulatory approval, deliver long-term manufacturing efficiencies and lower unit costs to support improved gross margins. Subsequent events: OncoSil receives $1.84 million R&D tax incentive In January 2026, OncoSil Medical has received a $1.84 million R&D Tax Incentive refund relating to eligible Australian and international R&D activities undertaken in FY25. The refund was received under the Australian Federal Government’s R&D Tax Incentive program, which provides a 43.5% cash rebate on eligible R&D expenditure to support innovation and research investment. OncoSil Medical Advances European Expansion with New Clinical Adoptions in Türkiye and Germany In January 2026, OncoSil Medical achieved two key international expansion milestones with the successful first OncoSil™ treatments performed at key hospitals in Türkiye and Germany. The first treatment at Acibadem Maslak Hospital in Istanbul, Türkiye was completed on 14 January 2026, a flagship hospital within the Acibadem Health Group, one of the region’s largest private healthcare providers. ONCOSIL MEDICAL LIMITED ABN 89 113 824 141 ASX | OSL Level 5, 7 Eden Park Drive, Macquarie Park, NSW 2113 AUSTRALIA TELEPHONE +61 2 8935 9629 WEB www.oncosil.com 4 During the same month, the first OncoSil™ treatment was also successfully performed at Vivantes Neukölln Hospital in Berlin, part of the Vivantes Network for Health, Germany’s largest municipal hospital group and a leading centre for gastrointestinal oncology. This represented the second hospital in Germany to adopt OncoSil™, reinforcing growing clinical interest and momentum in Europe’s most significant healthcare market and supporting the Company’s strategy to expand physician awareness and accelerate uptake across key international regions. TRIPP-FFX Trial Completes Last Patient Last Visit In January 2026, OncoSil Medical has successfully completed Last Patient, Last Visit (LPLV) in the TRIPP- FFX clinical trial, marking the completion of all patient treatments and follow-up assessments for this study. TRIPP-FFX is a prospective, multi-centre study evaluating the safety and efficacy of the OncoSil™ device in addition to FOLFIRINOX chemotherapy in patients with unresectable locally advanced pancreatic cancer, with primary endpoints including safety, tolerability, and local disease control. A total of 88 patients were recruited across 15 sites in Europe and Australia, with recruitment completed in July 2025. Following LPLV, the Company will progress to final data cleaning, database lock, and statistical analysis, with results expected in 1H CY26 and a regulatory submission planned for 2H CY26 to expand the CE Mark to include FOLFIRINOX as an additional chemotherapy option. OncoSil™ delivers strong early clinical results in Türkiye In January 2026, OncoSil Medical announced very strong surgical resection outcomes at Ankara Bilkent City Hospital in Türkiye for patients with unresectable locally advanced pancreatic cancer treated with the OncoSil™ device alongside standard-of-care FOLFIRINOX chemotherapy. Among six patients treated at this high-volume centre, post-treatment responses included one complete response, four partial responses, and one case of stable disease, with five patients (83%) subsequently undergoing successful surgical resection with curative intent. This resection rate is materially higher than published benchmarks for LAPC treated with chemotherapy alone and exceeds earlier OncoSil™ clinical experience, including the PANCO trial, highlighting the potential of OncoSil™ to meaningfully increase resectability and improve outcomes in routine clinical practice. $8.0 million Capital Raise for Ongoing Commercial Expansion At the beginning of February 2026, OncoSil Medical announced a capital raising of approximately $8.0 million, comprising a two-tranche placement to sophisticated and professional investors and a fully underwritten pro rata non-renounceable entitlement offer. The placement will raise approximately $6.0 million through the issue of new shares and options at $0.68 per share, while the entitlement offer is expected to raise a further $2.0 million before costs, on the same terms, providing eligible shareholders the opportunity to participate in the capital raising. Authorisation & Additional Information This announcement was authorised by the Board of Directors of OncoSil Medical Ltd. ONCOSIL MEDICAL LIMITED ABN 89 113 824 141 ASX | OSL Level 5, 7 Eden Park Drive, Macquarie Park, NSW 2113 AUSTRALIA TELEPHONE +61 2 8935 9629 WEB www.oncosil.com 5 For further information, please contact: About OncoSil Medical OncoSil Medical (ASX:OSL) is a global medical device company focused on Interventional Oncology. OncoSil Medical’s mission is to improve the outcomes for people living with cancer by utilizing the selected and targeted intratumoural placement of Phosphorous-32 (32P) Microparticles in addition to chemotherapy. OncoSil Medical has developed OncoSil™ device for the treatment of unresectable locally advanced pancreatic cancer. Its targeted approach enables healthcare professionals to deliver a greater radiation dose directly into the tumour compared to external beam radiotherapy, while sparing surrounding critical organs. Pancreatic cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with 500,000 new cases detected every year1 . Since pancreatic cancer is generally diagnosed at a later stage, it has a poor prognosis for long-term survival. OncoSil™ has received CE Marking approval, providing marketing authorisation in both the EU and the UK. OncoSil™ is designated as a breakthrough device in both Europe and the United States. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Türkiye and Israel, with commercial treatments using the device already undertaken in Spain, Italy, Austria, Germany, Greece, Türkiye, Portugal, Israel and the UK. To learn more, please visit: www.oncosil.com/ 1. https://gco.iarc.fr/en Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 30 300 149 3043 Mr. Tim Luscombe Company Secretary E: tim.luscombe@bio101.com T: +61 429 707 079 Ms. Julia Maguire The Capital Network Media and Investor Enquiries E: julia@thecapitalnetwork.com.au T: +61 2 7257 7338 OncoSil Medical Ltd Appendix 4D Half-year report 1. Company details Name of entity: OncoSil Medical Ltd ABN: 89 113 824 141 Reporting period: For the half-year ended 31 December 2025 Previous period: For the half-year ended 31 December 2024 2. Results for announcement to the market $ Revenues from ordinary activities up 70.5% to 782,895 Other income and interest revenue up 329.3% to 2,443,913 Loss from ordinary activities after tax attributable to the owners of OncoSil Medical Ltd down 32.5% to (4,525,069) Loss for the half-year attributable to the owners of OncoSil Medical Ltd down 32.5% to (4,525,069) Dividends There were no dividends paid, recommended or declared during the current financial period. Comments The loss for the Group after providing for income tax amounted to $4,525,069 (31 December 2024: $6,706,801). Further information on the results is detailed in the 'Review of operations' section of the Directors' report which is part of the Interim Report. 3. Net tangible assets Reporting period Previous period Cents Cents Net tangible assets per ordinary security 20.42 74.36 Calculated as follows: Consolidated 31/12/2025 31/12/2024 $ $ Net assets 3,836,751 8,559,904 Less: Right-of-use assets (38,904) (67,254) Add: Lease liabilities 42,469 70,843 Net tangible assets 3,840,316 8,563,493 Number of shares 31/12/2025 31/12/2024 Number of shares on issue at 31 December 18,810,140 11,516,450 Number of shares on issue for the prior year has been restated for the share consolidation of every 400 pre-consolidation shares into 1. Approved by shareholders at EGM on 29 May 2025. OncoSil Medical Ltd Appendix 4D Half-year report 4. Control gained over entities Not applicable. 5. Loss of control over entities Not applicable. 6. Dividend reinvestment plans Not applicable. 7. Details of associates and joint venture entities Not applicable. 8. Foreign entities Details of origin of accounting standards used in compiling the report: Not applicable. 9. Audit qualification or review Details of audit/review dispute or qualification (if any): The financial statements were subject to a review by the auditors and the review report, which includes a paragraph addressing a material uncertainty related to going concern, is attached as part of the Interim Report. 10. Attachments Details of attachments (if any): The Interim Report of OncoSil Medical Ltd for the half-year ended 31 December 2025 is attached. 11. Signed On behalf of the directors Signed ___________________________ Date: 24 February 2026 Dr Thomas Duthy Non-executive Chairman Sydney OncoSil Medical Ltd ABN 89 113 824 141 Interim Report - 31 December 2025 OncoSil Medical Ltd Directors' report 31 December 2025 1 The directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'Group') consisting of OncoSil Medical Ltd (referred to hereafter as the 'Company' or 'parent entity') and the entities it controlled at the end of, or during, the half-year ended 31 December 2025. Directors The following persons were directors of OncoSil Medical Ltd during the whole of the financial half-year and up to the date of this report, unless otherwise stated: Dr Thomas Duthy - Non-Executive Director & Chairman (appointed on 11 July 2025 and on 1 October 2025, respectively) Mr Douglas Cubbin - Non-Executive Chairman (resigned as Chairman on 1 October 2025 and as Non-Executive Director on 19 November 2025) Mr Nigel Lange - Chief Executive Officer and Managing Director Ms Lel Smits - Non-Executive Director Dr Gabriel Liberatore - Non-Executive Director (resigned on 11 July 2025) Principal activities The principal activities of the Group during the financial half-year focused on the development and commercialisation of its lead product candidate, the OncoSil™ localised radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. Review of operations The loss for the Group after providing for income tax amounted to $4,525,069 (31 December 2024: $6,706,801). OncoSil Medical Ltd is an ASX-listed medical device company which has developed a breakthrough implantable radiation (brachytherapy) device for patients with pancreatic cancer. The OncoSil™ device has CE Marking approval for the treatment of locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. Throughout the six-month period to 31 December 2025, OncoSil continued to progress its commercialisation activities across approved markets in Europe, the United Kingdom and the Middle East. Commercialisation Throughout HY25, OncoSil continues to expand its global reach and successfully initiated several new commercial and clinical programs: ● First patient treatment in Portugal: On 2 October 2025, the first OncoSil™ device implantation was completed in Portugal at Instituto Português de Oncologia do Porto FG (IPO Porto), marking the commencement of OncoSil’s commercial activities in the Portuguese market. ● First patient treatment in Germany: On 15 October 2025, the first OncoSil™ device implantation was completed in Germany at Universitätsklinikum Ausburg, marking the commencement of OncoSil’s commercial activities in Germany, the largest and most influential healthcare market in Europe. ● First patient commercial treatment in United Kingdom (UK): On 9 December 2025, the first commercial patient treatment in the UK took place at Southampton General Hospital (University Hospital Southampton NHS Foundation Trust). This significant milestone marks the transition from clinical trial involvement to the commencement of OncoSil’s commercial operations in the UK. ● Successful test production run at Sydney manufacturing facility: On 17 December 2025, the Company announced the successful completion of the first hot (radio-activated) production test run at its Sydney manufacturing facility. Clinical and regulatory affairs OncoSil continued to make significant progress in advancing its clinical and regulatory programs: ● Patient recruitment completed in TRIPP-FXX and PANCOSIL clinical trials: The investigator-initiated PANCOSIL trial reached 100% recruitment with the 20th patient treated at Amsterdam UMC on 4 July 2025. The TRIPP-FFX trial achieved 100% recruitment with the last patient being recruited on 23 July 2025. With the last patient, last visit for the TRIPP-FFX trial completed in January 2026, the Company is proceeding to final data cleaning and database lock. ● Positive Preliminary Results from PANCOSIL Phase 1-2 Study: In September 2025, preliminary results of the PANCOSIL Investigator Initiated Study revealed that it is safe and feasible to deliver OncoSil™ by CT-guided percutaneous administration. ● OSPREY analysis shows survival benefit for OncoSil patients: On 3 December 2025, the Company announced the interim findings from the OSPREY registry with a median overall survival of 20.6 months from diagnosis for those implanted with OncoSil™ at ≤ 4 months from starting chemotherapy and 22.0 months median overall survival from diagnosis for those implanted with OncoSil™ at 4-12 months from starting chemotherapy, observed in first-line patients within the OSPREY registry. OncoSil Medical Ltd Directors' report 31 December 2025 2 Corporate The Company underwent significant changes: ● Completed $2 million Share Purchase Plan (SPP): On 11 July 2025, the Company completed a $2 million SPP. ● $3.5m in new equity raised: On 14 July 2025, the Company raised $3.5 million by issuing 2,877,071 new shares at $1.20 each. Each share included an option, exercisable at $1.20 and expiring in 2 years (OSLOD). ● Appointment of Dr Thomas Duthy as Non-Executive Director: On 11 July 2025, the Company appointed Dr Thomas Duthy as a Non-Executive Director. Dr Duthy brings over 21 years of experience in healthcare, financial markets, and corporate development, including a key role in Sirtex Medical’s $1.9 billion acquisition. On the same day, Dr Gabriel Liberatore resigned from the Board for personal reasons. The Board thanked Mr Liberatore for his service. ● Appointment of Tim Luscombe and David Wood as Joint Company Secretaries: On 23 July 2025, Mr Nathan Kimliung Jong resigned as Company Secretary and Ms Olga Smejkalova appointed to the position on the same day. On 1 September 2025, Mr Tim Luscombe and Mr David Wood were appointed as Joint Company Secretaries and Ms Smejkalova resigned from the role on the same day. On 5 February 2026, Mr Wood resigned as Joint Company Secretary. In accordance with ASX Listing Rule 12.6, Mr Luscombe is now the person responsible for communication with the ASX. ● Appointment of Dr Thomas Duthy as Chairman: On 1 October 2025, Dr Duthy was appointed as Non-Executive Chairman of the Company. On the same day, Mr Douglas Cubbin stepped down as Chairman to become a Non-Executive Director. ● Retirement of Mr Douglas Cubbin as Non-Executive Director: On 3 November 2025, Mr Cubbin announced that he would retire as a Director of the Company, effective 19 November 2025. The Board thanked Mr Cubbin for his service. Financial position and performance OncoSil had a cash balance of $2,854,584 as at 31 December 2025 (30 June 2025: $5,109,692). During the half-year, OncoSil earned revenue from the sale of the OncoSil™ device of $782,895 (31 December 2024: $459,270). Recognised revenue from the Research and Development tax incentive in 2025 was $2,392,157 (31 December 2024: $526,113), reflecting the sustained and consistent investment the Company has towards Research and Development. Refer to note 2 for the directors’ assessment of going concern. Significant changes in the state of affairs On 11 and 14 July 2025, the Company issued a total of 4,604,117 fully paid ordinary shares and 7,623,054 attaching listed options (OSLOD), all exercisable and expiring on 31 July 2027. This comprised: ● 1,727,046 ordinary shares with 1,727,046 OSLOD options, consideration received was $2.0 million; and ● 2,877,071 ordinary shares with 5,583,343, 187,665, and 125,000 OSLOD options, consideration received was $3.5 million. Included in the 5,583,343 OSLOD options was Tranche 1 options of 2,706,272 attaching to Tranche 1 shares issued on 3 June 2025. There were no other significant changes in the state of affairs of the Group during the financial half-year. Business risks The material business risks that could adversely affect the Group's financial performance and growth potential in future years and how the Group propose to mitigate such risks were detailed in the Annual Report at 30 June 2025. Those risks have been assessed up to the reporting date with no significant changes noted since then. Environmental regulation The Group is not currently subject to any significant environmental regulation under Australian Commonwealth or State law. However, the following disclosure standard will soon become effective. AASB S2 ‘Climate-related Disclosures’ sets out specific climate related disclosures. It applies to entities required to prepare and lodge a financial report with ASIC under Chapter 2M and is effective for different entities based on certain criteria. The Company does not fall within Groups 1, 2, or 3 and is therefore not subject to mandatory climate‑related reporting requirements under AASB S2 at this time. OncoSil Medical Ltd Directors' report 31 December 2025 3 Auditor's independence declaration A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out immediately after this directors' report. This report is made in accordance with a resolution of directors, pursuant to section 306(3)(a) of the Corporations Act 2001. On behalf of the directors ___________________________ Dr Thomas Duthy Non-executive Chairman 24 February 2026 Sydney Crowe Sydney ABN 97 895 683 573 Level 24, 1 O’Connell Street Sydney NSW 2000 Main +61 (02) 9262 2155 Fax +61 (02) 9262 2190 www.crowe.com/au Some of the Crowe personnel involved in preparing this document may be members of a professional scheme approved under Professional Standards Legislation such that their occupational liability is limited under that Legislation. To the extent that applies, the following disclaimer applies to them. If you have any questions about the applicability of Professional Standards Legislation Crowe’s personnel involved in preparing this document, please speak to your Crowe adviser. Liability limited by a scheme approved under Professional Standards Legislation. The title ‘Partner’ conveys that the person is a senior member within their respective division, and is among the group of persons who hold an equity interest (shareholder) in its parent entity, Findex Group Limited. The only professional service offering which is conducted by a partnership is external audit, conducted via the Crowe Australasia external audit division and Unison SMSF Audit. All other professional services offered by Findex Group Limited are conducted by a privately owned organisation and/or its subsidiaries. Findex (Aust) Pty Ltd, trading as Crowe Australasia is a member of Crowe Global, a Swiss verein. Each member firm of Crowe Global is a separate and independent legal entity. Findex (Aust) Pty Ltd and its affiliates are not responsible or liable for any acts or omissions of Crowe Global or any other member of Crowe Global. Crowe Global does not render any professional services and does not have an ownership or partnership interest in Findex (Aust) Pty Ltd. Services are provided by Crowe Sydney, an affiliate of Findex (Aust) Pty Ltd. © 2026 Findex (Aust) Pty Ltd 4 Auditor’s Independence Declaration Under Section 307c of the Corporations Act 2001 to the Directors of OncoSil Medical Ltd As lead engagement partner, I declare that, to the best of my knowledge and belief, during the half- year ended 31 December 2025 there have been: (i) no contraventions of the auditor independence requirements as set out in the Corporations Act 2001 in relation to the review; and (ii) no contraventions of any applicable code of professional conduct in relation to the review. Yours sincerely, Crowe Sydney Barbara Richmond Partner 24 February 2026 Sydney OncoSil Medical Ltd Contents 31 December 2025 5 Statement of profit or loss and other comprehensive income 6 Statement of financial position 7 Statement of changes in equity 8 Statement of cash flows 9 Notes to the financial statements 10 Directors' declaration 21 Independent auditor's review report to the members of OncoSil Medical Ltd 22 OncoSil Medical Ltd Statement of profit or loss and other comprehensive income For the half-year ended 31 December 2025 Consolidated Note 31/12/2025 31/12/2024 $ $ The above statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes 6 Revenue 4 782,895 459,270 Other income 5 2,392,157 526,113 Interest revenue calculated using the effective interest method 51,756 43,131 Expenses Raw materials and consumables used 6 (1,382,270) (984,848) Employee benefits expense (2,362,642) (2,355,289) Research and development expenses (2,398,639) (1,39